These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 34152636)
1. SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501. Macaluso FS; Cappello M; Busacca A; Fries W; Viola A; Costantino G; Magnano A; Vinci E; Ferracane C; Privitera AC; Piccillo G; Belluardo N; Giangreco E; Romano C; Citrano M; Graziano F; Garufi S; Bertolami C; Ventimiglia M; Scrivo B; Teresi G; Renna S; Rizzuto G; Casà A; Orlando A; J Gastroenterol Hepatol; 2021 Nov; 36(11):3041-3049. PubMed ID: 34152636 [TBL] [Abstract][Full Text] [Related]
2. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study. Casanova MJ; Nantes Ó; Varela P; Vela-González M; Rivero M; Sierra-Gabarda O; Riestra S; Barreiro-de Acosta M; Martín-Rodríguez MDM; Gargallo-Puyuelo CJ; Reygosa C; Muñoz R; de la Filia-Molina IG; Núñez-Ortiz A; Kolle L; Calafat M; Huguet JM; Iglesias-Flores E; Martínez-Pérez TJ; Bosch O; Duque-Alcorta JM; Frago-Larramona S; Van Domselaar M; González-Cosano VM; Bujanda L; Rubio S; Mancebo A; Castro B; García-López S; de Francisco R; Nieto-García L; Laredo V; Gutiérrez-Casbas A; Mesonero F; Leo-Carnerero E; Cañete F; Ruiz L; Gros B; Del Moral-Martínez M; Rodríguez C; Chaparro M; Gisbert JP Aliment Pharmacol Ther; 2023 Jul; 58(1):60-70. PubMed ID: 37089065 [TBL] [Abstract][Full Text] [Related]
3. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Pica R; Pranzo G; Rodino' S; Scarcelli A; Zampaletta C; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Faggiani R; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Picchio M; Sacco R; Sebkova L; Serio M; Napolitano D; Pugliese D; Scaldaferri F; Schiavoni E; Turchini L; Armuzzi A; Elisei W; Maconi G; Papa A Inflamm Bowel Dis; 2023 Mar; 29(3):376-383. PubMed ID: 35579320 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. Derikx LAAP; Dolby HW; Plevris N; Lucaciu L; Rees CS; Lyons M; Siakavellas SI; Constantine-Cooke N; Jenkinson P; Su S; O'Hare C; Kirckpatrick L; Merchant LM; Noble C; Arnott ID; Jones GR; Lees CW J Crohns Colitis; 2021 Dec; 15(12):2011-2021. PubMed ID: 34089587 [TBL] [Abstract][Full Text] [Related]
5. Non-medical switch from the originator to biosimilar and between biosimilars of adalimumab in inflammatory bowel disease - a prospective, multicentre study. Lontai L; Gonczi L; Balogh F; Komlodi N; Resal T; Farkas K; Molnar T; Miheller P; Golovics PA; Schafer E; Szamosi T; Ilias A; Lakatos PL Dig Liver Dis; 2022 Dec; 54(12):1639-1645. PubMed ID: 35931624 [TBL] [Abstract][Full Text] [Related]
6. Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with inflammatory bowel disease: results of a multicenter survey. Sarlós P; Bikar A; Farkas N; Resál T; Szepes Z; Farkas K; Nagy F; Vincze Á; Miheller P; Molnár T Expert Opin Biol Ther; 2023; 23(8):827-832. PubMed ID: 37161387 [TBL] [Abstract][Full Text] [Related]
7. The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches. Macaluso FS; Fries W; Viola A; Centritto A; Cappello M; Giuffrida E; Privitera AC; Piccillo G; Magnano A; Vinci E; Vassallo R; Trovatello A; Belluardo N; Giangreco E; Camilleri S; Garufi S; Bertolami C; Ventimiglia M; Renna S; Orlando R; Rizzuto G; Orlando A Inflamm Bowel Dis; 2021 Jan; 27(2):182-189. PubMed ID: 32083291 [TBL] [Abstract][Full Text] [Related]
8. Real-World Experience of Adalimumab Biosimilar (ABP 501) Use in Patients with Inflammatory Bowel Disease in Europe. Jin R; Nduka C; Courmier D; Knight H; Meadows R; Piercy J; Cummings JRF; Radziszewski W Adv Ther; 2024 Jan; 41(1):331-348. PubMed ID: 37957522 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Scrivo R; Castellani C; Mancuso S; Sciarra G; Giardina F; Bevignani G; Ceccarelli F; Spinelli FR; Alessandri C; Di Franco M; Riccieri V; Priori R; Conti F Clin Exp Rheumatol; 2023 Mar; 41(3):613-619. PubMed ID: 35916302 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. Ribaldone DG; Caviglia GP; Pellicano R; Vernero M; Saracco GM; Morino M; Astegiano M Rev Esp Enferm Dig; 2020 Mar; 112(3):195-200. PubMed ID: 32054272 [TBL] [Abstract][Full Text] [Related]
11. Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. Cingolani L; Barberio B; Zingone F; Ferronato A; Bertani L; Costa F; Bodini G; Demarzo MG; Melatti P; Gubbiotti A; Massimi D; Casadei C; D'Incà R; Savarino EV Sci Rep; 2021 May; 11(1):10368. PubMed ID: 33990652 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry. Tapete G; Bertani L; Pieraccini A; Lynch EN; Giannotta M; Morganti R; Biviano I; Naldini S; Mumolo MG; De Nigris F; Calella F; Bagnoli S; Minciotti M; Maltinti S; Rentini S; Ceccarelli L; Lionetti P; Milla M; Costa F Inflamm Bowel Dis; 2022 Jan; 28(1):62-69. PubMed ID: 33570142 [TBL] [Abstract][Full Text] [Related]
13. Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy. Tursi A; Mocci G; Cuomo A; Ferronato A; Elisei W; Picchio M; Maconi G; Scaldaferri F; Papa A; ; Allegretta L; Aragona G; Bianco MA; Colucci R; Della Valle N; Faggiani R; Forti G; Gaiani F; Giorgetti G; Graziani MG; Lofano K; Lorenzetti R; Larussa T; Penna A; Bassotti G; Cazzato AI; Chiri S; Clemente V; Cocco A; De' Angelis G; Donnarumma L; Graziosi C; Le Grazie M; Luzza F; Meucci C; Monterubbianesi R; Pagnini C; Perazzo P; Pica R; Pranzo G; Rodino' S; Sacco R; Sebkova L; Scarcelli A; Serio M; Napolitano D; Pugliese D; Schiavoni E; Turchini L; Armuzzi A; Zampaletta C J Gastrointestin Liver Dis; 2022 Dec; 31(4):411-416. PubMed ID: 36535057 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn's disease. Viscido A; Latella G Rev Esp Enferm Dig; 2021 Feb; 113(2):154-155. PubMed ID: 33207902 [TBL] [Abstract][Full Text] [Related]
16. OBSIDIAN - real-world evidence of originator to biosimilar drug switch in juvenile idiopathic arthritis. Maccora I; Lombardi N; Crescioli G; Bettiol A; Bonaiuti R; Pagnini I; Maniscalco V; Marrani E; Mastrolia MV; Ravaldi C; Consolini R; Cattalini M; Vannacci A; Simonini G Rheumatology (Oxford); 2022 Apr; 61(4):1518-1528. PubMed ID: 34273158 [TBL] [Abstract][Full Text] [Related]
17. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial. Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR; Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564 [TBL] [Abstract][Full Text] [Related]
18. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre. Lukas M; Malickova K; Kolar M; Bortlik M; Vasatko M; Machkova N; Hruba V; Duricova D; Lukas M J Crohns Colitis; 2020 Jul; 14(7):915-919. PubMed ID: 31905382 [TBL] [Abstract][Full Text] [Related]
19. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the Sicilian Network for Inflammatory Bowel Disease. Dipasquale V; Pellegrino S; Ventimiglia M; Cucinotta U; Citrano M; Graziano F; Cappello M; Busacca A; Orlando A; Accomando S; Romano C; Eur J Gastroenterol Hepatol; 2022 Oct; 34(10):1007-1014. PubMed ID: 35830365 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of the safety and effectiveness after switch from adalimumab originator to biosimilar SB5 in patients with inflammatory bowel disease in a real-life setting. Deprez N; De Somer T; Baert D; Deceuninck M; Huys I; Mattens V; Sterckx A; Vanderstraeten E; Vandervoort J; Van Heddegem N; Dewint P Acta Gastroenterol Belg; 2022; 85(4):557-564. PubMed ID: 36566364 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]